Since CD38 expression is a key determinant of susceptibility of MM cells to daratumumab-mediated ADCC and CDC, as well as clinical response, several groups are evaluating agents that increase CD38 protein levels to improve the efficacy of daratumumab. This evidence concerns the gene CD38 and Miyoshi myopathy.